BROSSARD, Quebec, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues based on Artificial Intelligence, is pleased to provide a corporate update on its major activities from 2021 operations. DIAGNOS would like to share some of the highlights and successes achieved this past year and also provide some insight into what we are working on for the upcoming year. Although COVID has presented many challenges for the Company, DIAGNOS was able to adjust and address a new Optometry market. The Company believes that the existing Government and Hospital clients should restart their coverage of diabetic patients this year.
DIAGNOS Provides Corporate Update for 2021 and Outlook for 2022
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
